Edwards Lifesciences
Edwards Lifesciences makes heart valves, its SAPIEN TAVR device leads the world.
On the record
Checkpoint: CMS final national coverage decision on asymptomatic aortic stenosis TAVR coverage
The call
Edwards keeps growing double digits and dominating TAVR while Medtronic pushes trial data and Boston Scientific tries to re-enter, with no share loss showing up yet.
Edwards Lifesciences sells replacement heart valves that doctors implant in patients, mostly for older adults. It is hard to copy because the company has spent nearly two decades running large clinical studies proving its valves work better, trained thousands of doctors to use them, and installed them in over 500,000 patients. Medtronic competes in the same market but with a smaller share, and Boston Scientific is trying to get back into the business, though neither has the clinical proof or doctor relationships Edwards built up. The one thing that could change the picture is if Medtronic's newer valve design starts winning away actual patients from Edwards in the next few quarters, which would show whether Edwards' advantages are really as strong as they look.
Why
01
AI pressure: None apparent. AI improves imaging and case selection around valve implants, it does not replace the hardware inside a patient's heart. Could AI do the core job? Unlikely.
02
Bigger players: Medtronic (Evolut). Medtronic's Evolut is live in TAVR with new trial data claiming better outcomes, but Edwards still holds roughly 55 to 66 percent share. Could a giant copy it? No, they are blocked.
03
What protects it. Decades of PARTNER trial data, per-indication FDA approvals, and 500,000-plus trained implanting physicians make switching slow and risky for hospitals.
What would change this call
Medtronic Evolut TAVR share vs Edwards SAPIEN over next two quarterly earnings. Would show if Medtronic's clinical trial data is converting into real market share gains.
CMS final decision on asymptomatic-AS TAVR coverage expansion. Would show whether Edwards' addressable TAVR market grows or stalls.
Boston Scientific TAVR product shipment or first commercial sales announcement. Would show whether Boston Scientific's re-entry becomes a real competitive threat.
CMS final decision on asymptomatic-AS TAVR coverage expansion. Would show whether Edwards' addressable TAVR market grows or stalls.
Boston Scientific TAVR product shipment or first commercial sales announcement. Would show whether Boston Scientific's re-entry becomes a real competitive threat.
Key numbers
- Q1 2026 revenue $1.65B, up 16.7% YoY
- FY2026 guidance raised to $6.5 to $6.9B
- Cash $2.4 to $3.0B versus $600M total debt
Named risks
- FTC blocked Edwards' $945M JenaValve deal and imposed a $12M settlement in July 2026, signaling tighter antitrust scrutiny on future M&A.
- Medtronic's Evolut showing favorable clinical outcomes as of May 2026 could erode Edwards' TAVR share over time.
- Boston Scientific's $1.5B TAVR re-entry investment disclosed May 2026 threatens the Edwards-Medtronic duopoly long term.
- CMS coverage expansion for asymptomatic severe AS faces pushback from medical societies like AATS, creating regulatory uncertainty.
- Discrepancy between officially reported headcount (16,000) and third-party workforce estimates raises data reliability questions.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Medtronic | contesting | Evolut shows favorable trial outcomes vs SAPIEN as of May 28, 2026; holds 28% TAVR share vs Edwards 55-66% |
| Boston Scientific | gaining on | Disclosed $1.5B investment in May 2026 to re-enter TAVR after 2019 exit; also rivals Edwards in LAA occlusion |
| Abbott | contesting | Competes via MitraClip/TriClip against Edwards PASCAL/EVOQUE; Navitor holds small TAVR share |
| AtriCure and Gore | contesting | Established LAA-occlusion rivals facing Edwards' new ECLIPTIS device cleared July 1, 2026 |
Questions people ask
- Is Edwards Lifesciences profitable in 2026?
- Yes. Edwards Lifesciences reported FY2025 revenue of $6.07 billion, up 10.7%, and Q1 2026 revenue of $1.65 billion, up 16.7% year over year, beating consensus, prompting the company to raise FY2026 guidance to $6.5-6.9 billion as of April 22, 2026.
- Could AI replace Edwards Lifesciences' heart valve products?
- No. Edwards makes physically implanted, FDA-regulated devices like SAPIEN valves and RESILIA tissue, backed by clinical trial data since 2007 and over 500,000 U.S. implants. AI tools like Philips' DeviceGuide, cleared March 27, 2026, only assist procedural imaging, not replace hardware.
- Who is Edwards Lifesciences' biggest competitor?
- Medtronic, via its Evolut TAVR platform, forming an effective duopoly with Edwards holding roughly 55-66% share versus Medtronic's 28% as of May 28, 2026. Boston Scientific is also investing $1.5 billion to re-enter TAVR as of May 2026.
- Is Edwards Lifesciences a safe company to join right now?
- Headcount stood at 16,000 at end of 2025, up slightly from 15,800 in 2024, after a sharp drop from 19,800 in 2023 tied to the September 2024 sale of its Critical Care unit to BD for $4.2 billion, not ongoing layoffs.
- Who owns Edwards Lifesciences?
- Edwards Lifesciences is an independent public company traded on the NYSE under ticker EW, with a market cap of roughly $44-50 billion as of mid-July 2026. It was spun off from Baxter in 2000 after Baxter's 1985 acquisition.
- Is Edwards Lifesciences facing antitrust trouble?
- Yes. A federal court granted the FTC a preliminary injunction in January 2026 blocking Edwards' $945 million JenaValve acquisition, and on July 13, 2026 Edwards and Genesis MedTech settled with the FTC and DOJ for $12 million total ($10 million from Edwards) over HSR filing violations tied to the JC Medical deal.
Timeline
- 2026-07-13Edwards and Genesis MedTech settle FTC/DOJ for $12M ($10M Edwards) over JC Medical HSR violations
- 2026-07-01FDA clears Edwards' ECLIPTIS LAA occlusion device, its first product outside TAVR/TMTT
- 2026-06-16CMS proposes expanding TAVR coverage to asymptomatic severe aortic stenosis patients
- 2026-05-01Boston Scientific discloses $1.5B investment toward re-entering TAVR market
- 2026-04-22Q1 2026 revenue hits $1.65B, up 16.7% YoY; Edwards raises FY2026 guidance to $6.5-6.9B
- 2026-03-27Philips gets FDA clearance for AI-powered DeviceGuide, co-developed with Edwards for PASCAL Ace
- 2026-02-10FY2025 revenue reported at $6.07B (+10.7%); Q4 2025 sales $1.57B (+13.3%)
- 2026-01-01Federal court grants FTC injunction blocking Edwards' $945M JenaValve acquisition
- 2025-05-01FDA expands SAPIEN 3 indication to asymptomatic severe aortic stenosis
- 2024-09-30Edwards completes $4.2B sale of Critical Care unit to Becton Dickinson
Revision history
22 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Edwards Lifesciences (EW) Earnings Transcript (2026-02-10)
- Edwards Lifesciences Reports First Quarter Results (2026-04-22)
- Edwards Lifesciences Reports Fourth Quarter Results (2026-02-10)
- Edwards' Q2 Earnings on the Horizon (2026-07-20)
- Edwards (2026-01-14)
- Medtronic's Evolut displays superior clinical outcomes (2026-05-28)
- Edwards Lifesciences (EW) Number of Employees 2000-2025 (2026-06-17)
- Edwards Lifesciences (EW) Current & Historical Employee Count (2025-02-28)
- Edwards' Q2 earnings on the horizon (2026-07-20)
- CMS Proposes Expanding TAVI Coverage to Asymptomatic Patients (2026-06-18)
- Philips wins FDA clearance for imaging device developed with Edwards (2026-03-27)
- Edwards Lifesciences Wins FDA Clearance for ECLIPTIS LAA System (2026-07-01)